Cardiovasc Prev Pharmacother.  2025 Jan;7(1):9-12. 10.36011/cpp.2025.7.e3.

The prognostic role of lipoprotein(a) in cardiovascular disease

• Rhee EJ

• KMID: 2564011
• DOI: http://doi.org/10.36011/cpp.2025.7.e3

Abstract

Lipoprotein(a) (Lp(a)), is not a new entity; however, it has become an increasingly discussed and studied risk factor for atherosclerotic cardiovascular disease (CVD) and aortic valve stenosis. Recent guidelines recommend measuring Lp(a) levels throughout the lifetime in patients at high risk for CVD, as Lp(a) can serve as a signature marker for identifying individuals at elevated risk for CVD. Numerous genetic and epidemiological studies have underscored the significant causal role of Lp(a) in the incidence of CVD. Individuals with high Lp(a) levels face an increased risk for CVD, even with optimal low-density lipoprotein cholesterol lowering. Furthermore, Lp(a) levels are primarily determined by genetics and are not significantly reduced by lifestyle changes or certain medications. This review will discuss the characteristics, genetic factors, and epidemiological properties of Lp(a) in relation to CVD.

Keyword

Lipoprotein(a); Cardiovascular diseases; Aortic valve stenosis

Reference

1. Duarte Lau F, Giugliano RP. Lipoprotein(a) and its significance in cardiovascular disease: a review. JAMA Cardiol. 2022; 7:760–9. DOI: 10.1001/jamacardio.2022.0987. PMID: 35583875.

2. Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol. 2016; 36:2239–45. DOI: 10.1161/atvbaha.116.308011. PMID: 27659098.

3. Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016; 57:1339–59. DOI: 10.1194/jlr.r067314. PMID: 27074913.

4. Jawi MM, Frohlich J, Chan SY. Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J Lipids. 2020; 2020:3491764. DOI: 10.1155/2020/3491764. PMID: 32099678.

5. Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022; 42:e48–60. DOI: 10.1161/atv.0000000000000147. PMID: 34647487.

6. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139:e1082–143. DOI: 10.1161/CIR.0000000000000625. PMID: 30586774.

7. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008; 117:176–84. DOI: 10.1161/circulationaha.107.715698. PMID: 18086931.

8. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009; 302:412–23. DOI: 10.1001/jama.2009.1063. PMID: 19622820.

9. Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, et al. Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. Arterioscler Thromb Vasc Biol. 2021; 41:465–74. DOI: 10.1161/atvbaha.120.315291. PMID: 33115266.

10. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009; 301:2331–9. DOI: 10.1001/jama.2009.801. PMID: 19509380.

11. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009; 361:2518–28. DOI: 10.1056/nejmoa0902604. PMID: 20032323.

12. Guddeti RR, Patil S, Ahmed A, Sharma A, Aboeata A, Lavie CJ, et al. Lipoprotein(a) and calcific aortic valve stenosis: a systematic review. Prog Cardiovasc Dis. 2020; 63:496–502. DOI: 10.1016/j.pcad.2020.06.002. PMID: 32526213.

13. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014; 63:470–7. DOI: 10.1016/j.jacc.2013.09.038. PMID: 24161338.

14. Arsenault BJ, Boekholdt SM, Dube MP, Rheaume E, Wareham NJ, Khaw KT, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet. 2014; 7:304–10. DOI: 10.1161/circgenetics.113.000400. PMID: 24704946.

15. Langsted A, Varbo A, Kamstrup PR, Nordestgaard BG. Elevated lipoprotein(a) does not cause low-grade inflammation despite causal association with aortic valve stenosis and myocardial infarction: a study of 100,578 individuals from the general population. J Clin Endocrinol Metab. 2015; 100:2690–9. DOI: 10.1210/jc.2015-1096. PMID: 25938632.

16. Bergmark BA, O’Donoghue ML, Murphy SA, Kuder JF, Ezhov MV, Ceska R, et al. An exploratory analysis of proprotein convertase subtilisin/kexin type 9 inhibition and aortic stenosis in the FOURIER Trial. JAMA Cardiol. 2020; 5:709–13. DOI: 10.1001/jamacardio.2020.0728. PMID: 32347887.

17. Gomez-Delgado F, Raya-Cruz M, Katsiki N, Delgado-Lista J, Perez-Martinez P. Residual cardiovascular risk: when should we treat it? Eur J Intern Med. 2024; 120:17–24. DOI: 10.1016/j.ejim.2023.10.013. PMID: 37845117.